<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028534</url>
  </required_header>
  <id_info>
    <org_study_id>C359kyoto</org_study_id>
    <nct_id>NCT01028534</nct_id>
  </id_info>
  <brief_title>Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)</brief_title>
  <official_title>Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare the effects of different types of antihypertensive
      drugs (angiotensin II receptor blockers and long-acting calcium channel blockers) in patients
      with hypertension and obstructive sleep apnea who are not controlled well with their
      hypertension after continuous positive airway pressure therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) and hypertension have a significant interrelationship, and both
      disorders are well known risk factors for cardiovascular diseases (CVD). Treating them
      appropriately may improve the prognosis of the patients. Presently, continuous positive
      airway pressure (CPAP) therapy is the first-line therapy for OSA, and angiotensin II receptor
      blockers and long-acting calcium channel blockers for hypertension in Japan. Therefore, in
      the present study, we wanted to compare the effects of these different types of
      antihypertensive drugs on the control of blood pressure in patients with OSA whose
      hypertension is not controlled well after CPAP therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial dysfunction</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality and sleepiness</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ARB plus increased ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB plus CCB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCB plus ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan and Azelnidipine</intervention_name>
    <description>Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months
Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months
Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months</description>
    <arm_group_label>ARB plus increased ARB</arm_group_label>
    <arm_group_label>ARB plus CCB</arm_group_label>
    <arm_group_label>CCB plus ARB</arm_group_label>
    <other_name>Olmesartan (angiotensin II receptor blockers: ARB)</other_name>
    <other_name>Azelnidipine (long-acting calcium channel blockers: CCB)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apnea and hypopnea index of more than 20 /hr, and treated with CPAP

          -  Uncontrolled hypertension (defined as systolic blood pressure of more than 130 mmHg or
             diastolic blood pressure of more than 80 mmHg

        Exclusion Criteria:

          -  Cerebrovascular diseases, myocardial infarction, angina pectoris or heart failure
             within 6 months

          -  Uncontrolled arrhythmia

          -  Severe hepatic or renal disorders

          -  Having poor prognosis disorders such as malignant disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuo Chin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Graduate School of Medicine, Kyoto University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toru Oga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Graduate School of Medicine, Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirigaoka Tsuda Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Toru Oga</investigator_full_name>
    <investigator_title>Respiratory Care and Sleep Control Medicine, Kyoto University, Graduate School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Continuous positive pressure ventilation</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Oxygen desaturation index</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Patient reported measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

